Evolus (NASDAQ: EOLS) has recently received a number of price target changes and ratings updates:
- 9/16/2024 – Evolus had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 9/13/2024 – Evolus had its price target raised by analysts at Barclays PLC from $16.00 to $20.00. They now have an “overweight” rating on the stock.
- 9/13/2024 – Evolus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
- 9/9/2024 – Evolus had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 8/1/2024 – Evolus had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
- 8/1/2024 – Evolus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Evolus Stock Up 2.0 %
Shares of EOLS traded up $0.33 during midday trading on Friday, hitting $16.77. The stock had a trading volume of 133,253 shares, compared to its average volume of 577,954. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -15.97 and a beta of 1.30. The company has a 50 day simple moving average of $14.19 and a two-hundred day simple moving average of $13.12. Evolus, Inc. has a twelve month low of $7.44 and a twelve month high of $17.70. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.
Evolus (NASDAQ:EOLS – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. On average, analysts anticipate that Evolus, Inc. will post -0.64 EPS for the current year.
Insider Activity at Evolus
Hedge Funds Weigh In On Evolus
Institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC acquired a new stake in Evolus during the 2nd quarter worth approximately $43,000. Quarry LP acquired a new stake in shares of Evolus during the second quarter worth $54,000. Tradition Wealth Management LLC boosted its position in shares of Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 2,475 shares during the period. Sierra Summit Advisors LLC acquired a new position in shares of Evolus in the fourth quarter valued at about $119,000. Finally, Profund Advisors LLC acquired a new position in shares of Evolus in the second quarter valued at about $130,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Stories
- Five stocks we like better than Evolus
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Profitably Trade Stocks at 52-Week Highs
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
- How to Read Stock Charts for Beginners
- Mastercard: Investing in AI and Cybersecurity to Beat Out Visa
Receive News & Ratings for Evolus Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus Inc and related companies with MarketBeat.com's FREE daily email newsletter.